Amid the prolonged sluggish trend in the IPO market in the pharmaceutical bio industry, attention is being paid to whether newly challenged companies will be able to draw a turnaround. According to the pharmaceutical industry on the 19th, there are two pharmaceutical bio companies that have been listed in the second quarter of this year, Wonteg and RP BIO.

On top of that, Immunemed, Lunit, and Shaperon have proposed listing on KOSDAQ within the first half of the year. However, they have not yet been approved for a preliminary screening of the listing. RP BIO passed a preliminary review for listing on KOSDAQ on the 14th. It has been about four months since it filed a preliminary review in December last y